Put on a cap and watch a cartoon.
That is roughly how PRISM gets described, and the skepticism is fair. Anyone who has met a brain-training headband ad has earned some.
The short answer to how PRISM works for PTSD: a cap records electrical activity at your scalp, software turns part of that into one moving signal, and the signal drives an animated scene while you practice settling it.
Scalp EEG cannot directly record a structure as deep as the amygdala, though. What moves on that screen is a model’s best estimate of amygdala-related activity.
If you are in crisis or thinking about harming yourself, call or text 988 for the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room. Our Fort Worth office is 817-659-7344; we are an outpatient practice, not a crisis service.
How does PRISM work for PTSD during a session?
Our PRISM for PTSD page puts it plainly: “During each PRISM session, you wear a comfortable EEG cap while you watch a scene on a computer screen filled with animated characters.” When you are on guard the scene looks tense; when you settle, so does it.
You and your clinician hunt for a mental strategy that quiets the scene, an image, a memory, the breath, and the screen shows within seconds whether it landed. That loop is the intervention.
Notice what is absent. No current, no magnetic field, no light and no infrared. PRISM is a brand name, not a light-based therapy. Unlike TMS, which delivers magnetic pulses through a coil, this device does not stimulate. It only records. That is the mechanism, not a claim that PRISM suits everyone; whether it fits you is a decision for a clinician who knows your history.
Low risk is not no risk. In the trial the FDA reviewed, 50.6% of subjects (40 of 79) had an adverse event, mostly mild headache and fatigue that cleared right after the session. Two serious adverse events occurred (2.53%), neither judged related to the software or the EEG device. The rest is practical: cap gel, sitting still for most of an hour, and trauma-script sessions meant to raise some distress. Say so if that becomes too much; the pace is adjustable.
We schedule about 15 sessions across 6 to 8 weeks, visits of roughly 45 minutes. The FDA summary describes “15, 30-minute sessions” twice weekly across 8 weeks, so the 45 minutes is the booked visit, not a longer treatment.
If scalp EEG cannot reach the amygdala, what is the animation responding to?
Scalp electrodes pick up activity near the surface, and the amygdala sits deep in the temporal lobe. A 2026 Molecular Psychiatry paper by Brandman and colleagues says EEG has “lower spatial resolution” than fMRI and is weakest at “deeply located nuclei such as the amygdala.”
So the signal is not an amygdala reading. It is a model.
The method comes from Meir-Hasson and colleagues in NeuroImage in 2014: record EEG and fMRI at once in the same people, then train a model to predict the deep signal from surface EEG alone. In Biological Psychiatry in 2016, Keynan and colleagues found the fingerprint “reliably predicts amygdala-blood oxygen level-dependent activity.” Predicts. Not measures or images.
In 71 healthy volunteers, Brandman’s group found the signal tracked a whole network the brain uses to flag what matters: the anterior insula, the dorsal anterior cingulate cortex, and the amygdala subregions that fire alongside them. So we will not tell you PRISM retrains your amygdala. The scene responds to a model-derived signal calibrated against amygdala-related activity while you practice self-regulation.
What makes this a medical device and not brain training?
The dividing line is regulatory. Under the FDA’s General Wellness guidance, a low-risk product stays outside device premarket review while its claims stay “unrelated to the diagnosis, cure, mitigation, prevention, or treatment of a disease or condition.” Claim to treat a named disorder and you are on the device side.
PRISM is on the device side: a GrayMatters Health product, cleared by the FDA on March 17, 2023 under 510(k) number K222101, Class II, prescription only, biofeedback. Its cleared indication opens with relaxation and stress reduction through EEG biofeedback, then names the condition: “indicated as an adjunctive treatment of symptoms associated with posttraumatic stress disorder (PTSD), to be used under the direction of a healthcare professional, together with other pharmacological and/or non-pharmacological interventions.”
Two words carry the weight. Cleared means GrayMatters showed the FDA that PRISM is substantially equivalent to two biofeedback devices already on the market, a regulatory threshold rather than a finding that it works better than anything. Adjunctive means alongside your other PTSD care.
The FDA record for K222101 never uses the words amygdala, fMRI, or biomarker. It describes software that processes EEG so a patient can learn to control EEG activity. The amygdala framing comes from the manufacturer and from published research.
What the research shows, and where it stops
The registration trial, by Fruchter and colleagues in Psychiatry Research in 2024, was single-arm and open-label: 15 sessions over 8 weeks. Its endpoint asked whether at least half of participants would improve by 6 points or more on the CAPS-5, the standard clinician-administered PTSD interview; the investigators set that bar themselves. At three months 66.7% did, averaging a 13.5-point drop. With no control group and no blinding, that cannot be separated from time, attention, and expectation. The FDA’s analysis of the 66-patient efficacy set shows the spread: two thirds cleared 6 points, about one in four improved by 21 or more.
The randomized proof-of-concept study before it, in NeuroImage: Clinical in 2021, had 40 completers in three arms. Feedback paired with a personal trauma script beat a no-neurofeedback control, 35.13% versus 0.23% symptom reduction. Against an arm given the same brain signal with neutral, non-trauma content, the difference was marginal (p = 0.07). That comparison isolates the trauma script, not the amygdala-derived signal, which no trial has separated out. Those authors called for a controlled trial to weigh the contribution of targeting the amygdala “over and above exposure, and possible placebo effects.”
The wider picture stays unsettled. A 2023 systematic review in the European Journal of Psychotraumatology pooled 7 randomized trials in 215 participants, found a large effect on PTSD symptoms (SMD -1.76), then graded that evidence very low in certainty, found significant risk of bias in eight of its ten controlled studies, and concluded the effect was moderate. An August 2025 Defense Health Agency fact sheet adds that the 2023 VA/DoD Clinical Practice Guideline, the American Psychological Association, and NICE all find insufficient evidence to recommend for or against neurofeedback for PTSD. Those statements cover neurofeedback as a category; the sheet notes clinicians may consider it for patients who have not responded to, or do not prefer, recommended treatments.
Where PRISM fits, and what we still do not know
The VA’s National Center for PTSD states that trauma-focused psychotherapies are the most effective treatments for PTSD, naming Cognitive Processing Therapy, Prolonged Exposure, and EMDR. PRISM’s clearance places it beside that care, not ahead of it.
Use aimed at anhedonia or depression is off-label, because PRISM is cleared only for PTSD in adults. The manufacturer’s depression protocol trains a different reward-system signal, carries GrayMatters’ own “FDA exempt – general wellness” label, and rests on a 2025 multicenter pilot in Brain Sciences in which 34 of 49 adults screened completed ten sessions. General wellness is not a lighter grade of clearance; it means the FDA has not reviewed that protocol for depression at all. Early, off-label, investigational, and a case-by-case conversation with your clinician rather than something we advertise.
Two gaps sit in the evidence itself. No published trial of this device has compared it against sham feedback, and the one randomized study used blinded raters but unblinded patients. So how much of the benefit comes from the signal, and how much from practicing self-regulation under a clinician’s attention, is unknown.
We also do not know how long gains hold, or how closely the studied group resembles you. The FDA file describes adults aged 22 to 65 with chronic PTSD, on average about ten years past the index trauma, most reporting military-related symptoms. Four of the five sites were in Israel, so how well that transfers to a Fort Worth outpatient population is open. And no study has compared PRISM head to head against psychotherapy or medication.
Frequently asked questions
Is PRISM FDA-cleared for PTSD, and what does clearance mean?
GrayMatters Health received 510(k) clearance K222101 on March 17, 2023 for adjunctive treatment of symptoms associated with PTSD in adults, under a clinician’s direction and alongside other treatment. Clearance is not drug approval. It rests on substantial equivalence to biofeedback devices already marketed, a regulatory threshold rather than a measure of how well the device works.
Does PRISM hurt, and are there side effects?
Nothing is delivered into the brain, so there is no current, coil pulse, or sedation to feel. In the trial the FDA reviewed, 50.6% of subjects reported an adverse event, mostly mild headache and fatigue that cleared right after the session. The larger demand is emotional: trauma-script sessions are designed to raise some distress.
Do I keep my therapy and medication while I do PRISM?
Yes. The clearance itself calls PRISM adjunctive, “to be used under the direction of a healthcare professional, together with other pharmacological and/or non-pharmacological interventions.” Nothing here is a reason to step away from trauma-focused therapy, and do not start, stop, or change a psychiatric medication without talking with your prescriber.
What does PRISM cost?
We are a self-pay practice, so PRISM is paid out of pocket, and a typical course runs about 15 sessions. Rates change, so check our current Price List and ask the office what a course involves before you commit.
What happens after the 15 sessions?
Your other treatment continues; PRISM is cleared as adjunctive, not as a course you graduate from. The registration trial followed people to three months, where 66.7% had improved by 6 points or more on the CAPS-5. What happens past that point is not something the published data answer, and whether a repeat course helps is not established. We reassess and decide with you.
The bottom line
PRISM is a real medical device with a narrow clearance: FDA-cleared in 2023 as an adjunctive treatment for PTSD symptoms in adults, prescription only. The signal behind the animated scene is a model’s estimate of amygdala-related activity, and the skill being trained is your own. The registration trial was positive; it was also single-arm and open-label, no trial of this device has been sham-controlled, and guideline bodies still call the neurofeedback evidence insufficient. Consider it for what it is cleared to be.
Talk with us
If you are in Fort Worth or the surrounding North Texas area and what you have read here sounds familiar, we would be glad to talk it through with you. The Institute for Advanced Psychiatry is an outpatient practice at 6800 Harris Parkway, Suite 100, treating adults 18 and older. You can request an appointment or call 817-659-7344.
If you are in crisis or thinking about harming yourself, please do not wait for an appointment. Call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7, or go to your nearest emergency room.
Sources
- U.S. Food and Drug Administration, Center for Devices and Radiological Health. “510(k) Premarket Notification Clearance Letter and 510(k) Summary, K222101 (Prism, GrayMatters Health Ltd.).” Decision date 2023-03-17. https://www.accessdata.fda.gov/cdrh_docs/pdf22/K222101.pdf
- U.S. Food and Drug Administration. “Learn if a Medical Device Has Been Cleared by FDA for Marketing.” Accessed 2026-09-02. https://www.fda.gov/medical-devices/consumers-medical-devices/learn-if-medical-device-has-been-cleared-fda-marketing
- U.S. Food and Drug Administration. “General Wellness: Policy for Low Risk Devices – Guidance for Industry and Food and Drug Administration Staff.” Issue date January 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices
- GrayMatters Health. “Regulatory.” Accessed 2026-09-02. https://www.graymatters-health.com/regulatory
- GrayMatters Health. “Prism Suite.” Accessed 2026-09-02. https://www.graymatters-health.com/prism-suite
- GrayMatters Health. “U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD.” 2023. https://www.prnewswire.com/news-releases/us-fda-grants-graymatters-health-510k-clearance-to-market-prism-for-ptsd-301777149.html
- Meir-Hasson Y, Kinreich S, Podlipsky I, Hendler T, Intrator N. “An EEG Finger-Print of fMRI deep regional activation.” NeuroImage 2014;102 Pt 1:128-141. https://doi.org/10.1016/j.neuroimage.2013.11.004
- Keynan JN, Meir-Hasson Y, Gilam G, et al. “Limbic Activity Modulation Guided by Functional Magnetic Resonance Imaging-Inspired Electroencephalography Improves Implicit Emotion Regulation.” Biological Psychiatry 2016;80:490-496. https://doi.org/10.1016/j.biopsych.2015.12.024
- Brandman T, Stern Y, Gurevitch G, et al. “An fMRI-informed EEG model of the amygdala is associated with salience network dynamics during naturalistic emotional stimulation.” Molecular Psychiatry 2026;31(5):2520-2529. https://pmc.ncbi.nlm.nih.gov/articles/PMC13099433/
- Fruchtman-Steinbok T, Keynan JN, Cohen A, et al. “Amygdala electrical-finger-print (AmygEFP) NeuroFeedback guided by individually-tailored Trauma script for post-traumatic stress disorder: Proof-of-concept.” NeuroImage: Clinical 2021;32:102859. https://pmc.ncbi.nlm.nih.gov/articles/PMC8551212/
- Fruchter E, Goldenthal N, Adler LA, et al. “Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy.” Psychiatry Research 2024;333:115711. https://doi.org/10.1016/j.psychres.2023.115711
- Askovic M, Soh N, Elhindi J, Harris AWF. “Neurofeedback for post-traumatic stress disorder: systematic review and meta-analysis of clinical and neurophysiological outcomes.” European Journal of Psychotraumatology 2023;14(2):2257435. https://pmc.ncbi.nlm.nih.gov/articles/PMC10515677/
- Amital D, Gross R, Goldental N, et al. “Reward System EEG-fMRI-Pattern Neurofeedback for Major Depressive Disorder with Anhedonia: A Multicenter Pilot Study.” Brain Sciences 2025;15:476. https://doi.org/10.3390/brainsci15050476
- Psychological Health Center of Excellence, Defense Health Agency. “Neurofeedback for Posttraumatic Stress Disorder.” August 2025. https://health.mil/Reference-Center/Publications/2026/01/09/Neurofeedback-for-PTSD
- U.S. Department of Veterans Affairs, National Center for PTSD. “Understanding PTSD Treatment.” Accessed 2026-09-02. https://www.ptsd.va.gov/understand_tx/index.asp
Quoted above from our own site, not an independent source: Institute for Advanced Psychiatry, “PRISM for PTSD,” https://www.psychiatryfortworth.com/services/prism/
Medical disclaimer
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation for any individual. Reading it does not create a physician-patient relationship. Treatment decisions, including whether any medication or procedure is appropriate for you, should be made with a qualified clinician who knows your history. Do not start, stop, or change a psychiatric medication without talking to your prescriber. If you are experiencing a medical or mental health emergency, call 911 or 988.